Latest news
{{'2026-06-06T13:00:00Z' | dateFormatFilter}}
People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more likely to achieve greater than 5% weight loss than those who were switched to tirzepatide, in real-world data
{{'2026-06-05T23:30:00Z' | dateFormatFilter}}
Novo Nordisk’s investigational zenagamtide shows significant HbA1C reductions with up to 14.6% weight loss in adults with type 2 diabetes - presented at ADA 2026
{{'2026-06-03T06:00:52Z' | dateFormatFilter}}
Wegovy® pill launches in the UAE as Novo Nordisk expands global access to obesity care
Investors
Share price
{{priceData.date}} {{priceData.time}}
{{priceData.currentPrice}}
{{priceData.currency}}
Go to stock watch
{{priceData.change}} {{priceData.currency}}
